Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
SA Brown, N Pereira - Journal of personalized medicine, 2018 - mdpi.com
Variability in response to antiplatelet therapy can be explained in part by
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …
pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of …
CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls
M Ellithi, J Baye, RA Wilke - Pharmacogenomics, 2020 - Taylor & Francis
Pharmacogenetic variants can alter the mechanism of action (pharmacodynamic gene
variants) or kinetic processes such as absorption, distribution, metabolism and elimination …
variants) or kinetic processes such as absorption, distribution, metabolism and elimination …
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations
Antiplatelet therapy with clopidogrel is the current standard of care for coronary artery
disease patients undergoing a percutaneous coronary intervention. However, approximately …
disease patients undergoing a percutaneous coronary intervention. However, approximately …
Clopidogrel: a case for indication‐specific pharmacogenetics
JA Johnson, DM Roden, LJ Lesko… - Clinical …, 2012 - Wiley Online Library
The CYP2C19* 2 loss‐of‐function allele is associated with reduced generation of active
metabolites of clopidogrel. However, meta‐analyses have supported or discounted the …
metabolites of clopidogrel. However, meta‐analyses have supported or discounted the …
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy
SA Scott, K Sangkuhl, EE Gardner… - Clinical …, 2011 - Wiley Online Library
CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet
prodrug clopidogrel. A common loss‐of‐function allele, CYP2C19* 2 (c. 681G> A; …
prodrug clopidogrel. A common loss‐of‐function allele, CYP2C19* 2 (c. 681G> A; …
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
Pharmacogenomics of clopidogrel: evidence and perspectives
T Yin, T Miyata - Thrombosis research, 2011 - Elsevier
Clopidogrel has become the mainstay oral antiplatelet regimen to prevent recurrent
ischemic events after acute coronary syndromes or stent placement. However, there is …
ischemic events after acute coronary syndromes or stent placement. However, there is …
Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond
HG Xie, JJ Zou, ZY Hu, JJ Zhang, F Ye… - Pharmacology & …, 2011 - Elsevier
The widespread use of clopidogrel alone or in combination with aspirin has significantly
benefited patients with acute coronary syndrome who are managed medically or by …
benefited patients with acute coronary syndrome who are managed medically or by …
Clopidogrel pharmacogenetics: state-of-the-art review and the TAILOR-PCI Study
NL Pereira, CS Rihal, DYF So… - Circulation …, 2019 - Am Heart Assoc
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C,
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …
polypeptide 19)* 2 and* 3 alleles leads to a loss of functional protein, and carriers of these …
相关搜索
- cyp2c19 genotype clopidogrel therapy
- pharmacogenomic impact cyp2c19 variation
- pharmacogenomic impact clopidogrel therapy
- clopidogrel pharmacogenomics platelet inhibition
- cytochrome p450 clopidogrel therapy
- clopidogrel pharmacogenomics fda recommendations
- pharmacogenomics of clopidogrel evidence and perspectives
- cyp2c19 variation clopidogrel therapy